Skip to main content

Table 2 Patient characteristics

From: Intra-dialytic hypotension following the transition from continuous to intermittent renal replacement therapy

Characteristics

N = 213

Female sex

64 (30.0%)

Category

 Medical

120 (56.3%)

 Surgical

93 (43.7%)

Age (years)

62.7 (52.8; 72.2)

Admission weight (kg)

85 (71; 101)

Baseline estimated glomerular filtration rate

46 (25; 74)

Comorbidities

 Myocardial infarction

27 (12.7%)

 Diabetes

65 (30.5%)

 Congestive heart failure

34 (16.0%)

 Peripheral artery disease

17 (8.0%)

 Chronic lung disease

43 (20.2%)

 Malignancy

30 (14.1%)

 Moderate to severe liver disease

17 (8.0%)

 Charlson score

2 (1; 4)

Time from hospital admission to RRT (days)

5 (2; 12)

Number of transitions attempts

 1

198 (93.0%)

 2

12 (5.6%)

 3

3 (1.4%)

Time on CRRT before transition attempt (days)

5 (3; 10)

Time gap between CRRT and IRRT (h)

24.5 (15.3; 41.2)

Outcomes

 Death in the ICU

82 (38.5%)

 Death in hospital

93 (43.7%)

 Discharged from hospital without RRT

89 (41.8%)

 Discharged from hospital with RRT

31 (14.6%)

 Length of stay in the ICU (days)

23 (14; 42)

 Length of hospital stay (days)

38 (24; 65)

 

At CRRT discontinuation

Before IRRT

Severity of illness (n = 231 transitions)

 Total SOFA scoreb

9 (SD:4)

10 (SD:3)

 Vasopressor use

95 (41.1%)

102 (44.2%)

 VIS

0 (IQR: 0; 7.5)

0 (IQR: 0; 8.0)

 Mechanical ventilation

205 (88.7%)

201 (87.0%)

 Cumulative fluid balance (liters)

7.4 (IQR: 1,5; 14.1)

7.6 (IQR: 2.3; 15.2)

 Fluid accumulation (% of body weight)

8.3 (1.7; 16.7)

8.0 (2.7; 17.7)

  1. Data are presented in mean (standard deviation (SD)) or median (interquartile range (IQR)), where appropriate
  2. CRRT continuous renal replacement therapy, therapy, IRRT Intermittent renal replacement therapy, VIS vasoactive-inotropic score
  3. aNumber of times a transition from CRRT-to-IRRT occurred during intensive care unit (ICU) stay
  4. bDetailed components of the sequential organ failure assessment (SOFA) score are presented in Tables S5 of the Additional file 1: Appendix